Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Current Deferred Revenue (2017 - 2022)

Summit Therapeutics filings provide 6 years of Current Deferred Revenue readings, the most recent being $3.2 million for Q2 2022.

  • Quarterly Current Deferred Revenue fell 54.75% to $3.2 million in Q2 2022 from the year-ago period, while the trailing twelve-month figure was $3.2 million through Jun 2022, down 54.75% year-over-year, with the annual reading at $7.9 million for FY2021, 5.15% down from the prior year.
  • Current Deferred Revenue hit $3.2 million in Q2 2022 for Summit Therapeutics, down from $5.1 million in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $8.4 million in Q4 2020 and bottomed at -$35.9 million in Q2 2018.
  • Average Current Deferred Revenue over 5 years is -$1.9 million, with a median of -$962358.6 recorded in 2019.
  • The largest annual shift saw Current Deferred Revenue soared 673.06% in 2020 before it plummeted 54.75% in 2022.
  • Summit Therapeutics' Current Deferred Revenue stood at -$8.0 million in 2018, then skyrocketed by 81.79% to -$1.5 million in 2019, then soared by 673.06% to $8.4 million in 2020, then decreased by 5.15% to $7.9 million in 2021, then plummeted by 59.3% to $3.2 million in 2022.
  • Per Business Quant, the three most recent readings for SMMT's Current Deferred Revenue are $3.2 million (Q2 2022), $5.1 million (Q1 2022), and $7.9 million (Q4 2021).